The estimated Net Worth of Advisors, Inc. Rosalind is at least $4.57 Million dollars as of 14 December 2022. Advisors Rosalind owns over 15,215 units of Delcath Systems stock worth over $4,574,777 and over the last 4 years Advisors sold DCTH stock worth over $0.
Advisors has made over 11 trades of the Delcath Systems stock since 2020, according to the Form 4 filled with the SEC. Most recently Advisors bought 15,215 units of DCTH stock worth $55,078 on 14 December 2022.
The largest trade Advisors's ever made was buying 500,000 units of Delcath Systems stock on 28 June 2021 worth over $5,780,000. On average, Advisors trades about 38,487 units every 54 days since 2020. As of 14 December 2022 Advisors still owns at least 459,315 units of Delcath Systems stock.
You can see the complete history of Advisors Rosalind stock trades at the bottom of the page.
Advisors's mailing address filed with the SEC is 15 WELLESLEY STREET WEST, SUITE 326, TORONTO, A6, M4Y 0G7.
Over the last 5 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,192,084 units worth $8,856,388 . The most active insiders traders include Marco Taglietti, Gerard J Michel, and Advisors, Inc. Rosalind. On average, Delcath Systems executives and independent directors trade stock every 25 days with the average trade being worth of $242,307. The most recent stock trade was executed by Gil Aharon on 19 March 2024, trading 26,882 units of DCTH stock currently worth $100,001.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Delcath Systems executives and other stock owners filed with the SEC include: